Table 4 Active trials involving T cell-based therapies
NCT | Phase | Intervention | Target population | Location | Sample size | Key outcomes |
|---|---|---|---|---|---|---|
NCT02661282 | Phase I/II | Autologous, CMV antigen-specific T cells with TMZ | Newly diagnosed or recurrent glioblastoma | USA | 27 | MTD, immunological effects, PFS, OS |
NCT03170141 | Phase I | Intravenous administration of immunogene-engineered autologous T cells after depletion with fludarabine/cyclophosphamide | Recurrent glioblastoma, prior treatment with standard of care | China | 20 | Safety, response rate, OS, PFS |
NCT03344250 | Phase I | Adjuvant use of bi-armed activated T cells against EGFR and CD3, with TMZ/RT | Newly diagnosed glioblastoma | USA | 18 | MTD, immune changes, OS, PFS, pathology correlation |
NCT03347097 | Phase I | Engineered autologous T cells expressing a full anti-PD1 antibody, infused after TMZ/RT | Newly diagnosed glioblastoma | China | 40 | Adverse events, PFS, OR |
NCT03389230 | Phase I | Memory-enriched CAR-T therapy specific to HER-2 with a truncated CD19 | Recurrent high-grade glioma | USA | 42 | Adverse events, DLT, CAR-T detection, PFS, OS |
NCT03726515 | Phase I | EGFR-vIII directed CAR-T cells combined with pembrolizumab | Newly diagnosed MGMT-unmethylated glioblastoma, EGFRvIII +  | USA | 7 | Adverse events, OS, PFS, ORR |
NCT04003649 | Phase I | Nivolumab, ipilimumab, and IL13Rα2-directed CAR-T therapy together after resection of recurrence | Recurrent glioblastoma | USA | 60 | Adverse events, DLT, feasibility of therapy, OS |
NCT04045847 | Phase I | Intratumoral CD147 CAR-T cells | Recurrent glioblastoma, prior treatment with standard of care | China | 31 | Adverse events, DLT, MTD, clinical activity, CAR-T detection |
NCT04077866 | Phase I/II | TMZ alone vs TMZ with B7-H3 CAR-T cells via intraventricular/intratumoral injection | Recurrent or progressive glioblastoma with B7-H3 positivity | China | 40 | OS, adverse events, PFS, MTD, CAR-T detection, pharmacokinetics |
NCT04165941 | Phase I | Genetically modified, TMZ-resistant γδ T cells intratumorally following the completion of TMZ/RT | Newly diagnosed glioblastoma | USA | 12 | MTD, PFS, OS, biological activity |
NCT04214392 | Phase I | Chlorotoxin-directed CAR-T cells given via dual delivery | Recurrent glioblastoma with MMP2 positivity | USA | 36 | DLT, CAR-T cell detection, cytokine levels, OS, PFS, antigen expression levels |
NCT04717999 | Phase I | Intraventricular NKG2D CAR-T cell therapy | Recurrent Glioblastoma | Taiwan | 20 | DLT, ORR, PFS |